SURMOUNT-CN: Tirzepatide in Chinese Adults
Last verified November 2026 · Phase 3 · Finished; headline results published August 2024 · NCT05024032 ↗
Most of what is known about these drugs comes from trials in which participants were predominantly white and predominantly American or European, with mean baseline weights around 100 kg. Chinese populations develop metabolic disease at lower BMI thresholds, which means both the eligibility criteria and the expected response may differ. SURMOUNT-CN is a smaller trial than the main program and was designed to support regional approval, but it addresses a gap that the larger trials structurally cannot.
- Enrollment
- 210
- Duration
- 52 weeks of weekly injections plus standard safety follow-up
- Drug
- Tirzepatide
- Population
- Chinese adults 18 and over with a BMI of 28 or more, or 24 or more if a weight-related condition came with it, meaning high blood pressure, abnormal cholesterol, sleep apnea, heart disease or fatty liver. Type 2 diabetes was an exclusion. 210 people were randomized across 29 centers in China between September 2021 and December 2022, split roughly evenly by sex, averaging 36 years old, 91.8 kg and a BMI of 32.3. Of those, 95.7% finished the full year, an unusually high completion rate.
The Tirzepatide drug page covers the drug itself: its dosing, cost and side effects.
Primary endpoint
How much body weight came off over 52 weeks, and how many lost at least 5%
Treatment arm
15 mg: −17.5% (95% CI −19.7 to −15.3); 10 mg: −13.6% (95% CI −15.8 to −11.4)
Comparator
Placebo: −2.3%
Treatment difference: 15 mg vs placebo: −15.1 percentage points (95% CI −18.2 to −12.1; P<0.001); 10 mg vs placebo: −11.3 percentage points (95% CI −14.3 to −8.3; P<0.001)
Nearly nine in ten cleared 5% on either dose, against under a third on placebo. The 17.5% at the top dose comes close to the 20.9% the multinational trial reported, from a leaner starting point (a BMI of 32.3 against 38.0) and over 20 fewer weeks.
Secondary endpoints
| Endpoint | Treatment | Comparator | Difference |
|---|---|---|---|
| Lost at least a tenth of body weight Nearly three quarters at the top dose, the threshold where sleep apnea, fatty liver and blood sugar tend to improve. | 15 mg: 71.9%; 10 mg: 64.1% | Placebo: 14.5% | P<0.001 for both tirzepatide doses vs placebo |
| Lost at least 15% A clear majority at the top dose reached the band that starts to overlap the lower end of what sleeve gastrectomy delivers at one year. | 15 mg: 61.4%; 10 mg: 46.4% | Placebo: 2.9% | P<0.001 for both tirzepatide doses vs placebo |
| Lost at least a fifth Not one person on placebo got here, against nearly half at the top dose. | 15 mg: 43.7%; 10 mg: 22.6% | Placebo: 0% | P<0.001 for both tirzepatide doses vs placebo |
| Weight lost in kilograms The figure most likely to be misread. 16.1 kg looks small against the 23.6 kg the multinational trial reported at its top dose for people who stayed on treatment, but participants here started 13 kg lighter. As a percentage the two are much closer, and percentage is what matters clinically. | 15 mg: −16.1 kg; 10 mg: −12.3 kg | Placebo: −2.1 kg | P<0.001 for both tirzepatide doses vs placebo |
| Inches off the waist About 14.5 cm at the top dose, similar to the multinational trials, and especially relevant in a population where fat around the middle drives risk at lower body weights. | 15 mg: −14.5 cm; 10 mg: −11.4 cm | Placebo: −2.6 cm | 15 mg vs placebo: −11.8 cm (95% CI −14.4 to −9.3); 10 mg vs placebo: −8.7 cm (95% CI −11.2 to −6.2); P<0.001 for both |
| Top blood-pressure number (both doses combined, the only way the trial analyzed it) About 6 points more than placebo, roughly what adding a low-dose blood-pressure tablet achieves. The paper analyzed blood pressure for the two doses together, so there is no per-dose figure. | Tirzepatide 10 mg and 15 mg pooled: −9.6 mmHg | Placebo: −3.5 mmHg | Pooled tirzepatide vs placebo: −6.1 mmHg (95% CI −9.1 to −3.1; P<0.001), efficacy estimand per the trial's ClinicalTrials.gov results |
| Three-month average blood sugar Nobody here had diabetes, so this moves within the normal-to-prediabetic band rather than treating anything. | 15 mg: −0.46%; 10 mg: −0.45% | Placebo: −0.05% | Treatment difference at 15 mg: −0.41 percentage points vs placebo |
| Fasting insulin level (both doses combined) Down about 6.5 units from a starting average of 16 to 18, more than a third, against almost no change on placebo. Of all these results, it is the clearest sign that insulin resistance itself improved. | Tirzepatide 10 mg and 15 mg pooled: −6.5 mU/L | Placebo: −0.2 mU/L | Pooled tirzepatide vs placebo: −6.3 mU/L (95% CI −8.6 to −4.0), efficacy estimand per the trial's ClinicalTrials.gov results |
| Triglycerides, a blood fat (both doses combined) Down about 0.6 mmol/L (roughly 55 mg/dL) from a starting level near 150 mg/dL, against almost no change on placebo. | Tirzepatide 10 mg and 15 mg pooled: −0.63 mmol/L | Placebo: −0.05 mmol/L | Pooled tirzepatide vs placebo: −0.58 mmol/L (95% CI −0.79 to −0.37), efficacy estimand per the trial's ClinicalTrials.gov results |
| LDL cholesterol, the main artery-damaging fraction (both doses combined) No clear difference from placebo. Nothing in this class replaces a statin for someone who needs one. | Tirzepatide 10 mg and 15 mg pooled: −0.17 mmol/L | Placebo: −0.11 mmol/L | Pooled tirzepatide vs placebo: −0.06 mmol/L (95% CI −0.25 to 0.13), efficacy estimand per the trial's ClinicalTrials.gov results |
Adverse events
| Event | Treatment rate | Comparator rate |
|---|---|---|
| Nausea About a third on either dose, mostly mild to moderate, and bunched into the weeks when the dose was rising. Overall stomach-and-bowel rates looked like the multinational trials. | 15 mg: 32.4%; 10 mg: 30.0% | Placebo: 5.8% |
| Diarrhea The most common side effect, reported by about four in ten on either dose. | 15 mg: 40.8%; 10 mg: 40.0% | Placebo: 8.7% |
| Loss of appetite Logged as a side effect by convention, though it is how the drug works rather than something going wrong. | 15 mg: 28.2%; 10 mg: 27.1% | Placebo: 11.6% |
| Vomiting Rose with the dose, from about 11% to about 20%. | 15 mg: 19.7%; 10 mg: 11.4% | Placebo: 4.3% |
| Bloating Far above the placebo rate on either dose. | 15 mg: 12.7%; 10 mg: 18.6% | Placebo: 1.4% |
| Stopped the drug over a side effect Few people stopped over side effects (7 of 141 across the two tirzepatide doses, which the paper rounds to under 5%), in a trial where 95.7% of everyone enrolled completed the full 52 weeks. The drug was well tolerated as well as effective. | 15 mg: 7.0% (5/71); 10 mg: 2.9% (2/70) | Placebo: 1.4% (1/69) |
| Serious adverse events of any kind Small numbers (8, 3 and 6 people), higher than placebo at 15 mg and lower at 10 mg. No one died during the study. | 15 mg: 11.3%; 10 mg: 4.3% | Placebo: 8.7% |
Clinical significance
The result is broadly consistent with SURMOUNT-1 in direction and magnitude, which supports generalizing the drug's effect across populations. At 210 participants it is small, and one regional trial does not settle generalizability across every population that was underrepresented in the pivotal trials. That gap is a limitation of the evidence base for this whole class, not of this trial.
Who sells tirzepatide, and for how much
This trial tested Tirzepatide. Across the 734 sellers on this register, 453 publish a standing monthly cash price for compounded tirzepatide, from $69 a month, with a median of $228.28.
⛔ None of those sellers was in this trial. A compounded preparation is not the product studied here: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and its concentration is set by whichever pharmacy filled it. The result above is the strongest evidence available for tirzepatide and it was generated on something else. Every seller, with its price record.
Frequently Asked Questions
References
- 1.Zhao L, Cheng Z, Lu Y, Liu M, Chen H, Zhang M, Wang R, Yuan Y, Li X. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024. PMID: 38819983.
- 2.U.S. National Library of Medicine. A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight in China (SURMOUNT-CN) — Study Record. ClinicalTrials.gov, NCT05024032. 2024. https://clinicaltrials.gov/study/NCT05024032
- 3.WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004. PMID: 14726171.
- 4.Zhou BF; Cooperative Meta-Analysis Group of the Working Group on Obesity in China. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults — study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci. 2002. PMID: 12046553.
- 5.Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PMID: 35658024.
- 6.Mu Y, Bao X, Eliaschewitz FG, et al.; STEP 7 Study Group. Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2024. PMID: 38330988.
- 7.Gao L, Lee BW, Chawla M, et al. Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. Nat Med. 2023. PMID: 37231074.